Xponance Inc. Sells 304,792 Shares of Merck & Co., Inc. (NYSE:MRK)

Xponance Inc. decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 66.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,510 shares of the company’s stock after selling 304,792 shares during the period. Xponance Inc.’s holdings in Merck & Co., Inc. were worth $12,016,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Cowen Prime Advisors LLC acquired a new stake in Merck & Co., Inc. during the second quarter worth approximately $31,000. PARK CIRCLE Co increased its holdings in shares of Merck & Co., Inc. by 100.0% during the second quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock worth $31,000 after purchasing an additional 200 shares during the period. AlphaMark Advisors LLC bought a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $39,000. Lake Point Wealth Management bought a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $40,000. Finally, ShoreHaven Wealth Partners LLC increased its holdings in shares of Merck & Co., Inc. by 55.5% during the first quarter. ShoreHaven Wealth Partners LLC now owns 619 shares of the company’s stock worth $48,000 after purchasing an additional 221 shares during the period. Institutional investors and hedge funds own 71.83% of the company’s stock.

Several research analysts have recently commented on the stock. Truist Securities assumed coverage on shares of Merck & Co., Inc. in a report on Tuesday, July 27th. They set a “buy” rating and a $76.79 target price on the stock. SVB Leerink lifted their price objective on shares of Merck & Co., Inc. from $99.00 to $101.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Morgan Stanley cut shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $90.00 to $85.00 in a research note on Tuesday, September 7th. Zacks Investment Research raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price objective on the stock in a research note on Tuesday, August 24th. Finally, Truist began coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $92.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $91.09.

Shares of NYSE:MRK opened at $73.61 on Friday. The firm has a market cap of $186.33 billion, a PE ratio of 33.61, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The firm’s fifty day moving average is $75.80 and its 200-day moving average is $76.50. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.06 and a current ratio of 1.31. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $85.60.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 EPS for the quarter, hitting analysts’ consensus estimates of $1.31. The company had revenue of $11.40 billion for the quarter, compared to analyst estimates of $11.21 billion. Merck & Co., Inc. had a net margin of 11.48% and a return on equity of 50.93%. During the same quarter in the previous year, the business earned $1.37 earnings per share. Sell-side analysts forecast that Merck & Co., Inc. will post 5.51 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be issued a $0.65 dividend. The ex-dividend date is Tuesday, September 14th. This represents a $2.60 annualized dividend and a yield of 3.53%. Merck & Co., Inc.’s payout ratio is 43.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More: What are defining characteristics of a correction?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.